cancer, breast cancer, ovarian cancer, prostate cancer, or colorectal cancer.

24. (Canceled)

25. (Previously Presented) The method of claim 23 further comprising administering to said mammal a therapeutically effective amount of a compound selected from the group consisting of alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell-cycle inhibitor, enzymes, topoisomerase, inhibitors, anti-hormones, and anti-androgens.

26. (Previously Presented) The method of claim 25 wherein the cell-cycle inhibitor is a mitotic inhibitor.

27. (Previously Presented) The pharmaceutical composition of claim 16, comprising from about 0.001 ~~mg~~ to about 100 mg/kg/day ~~mg~~ of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.

Exam. Amdt. 12/1/08 TNT

28. (Previously Presented) The pharmaceutical composition of claim 16, comprising from about 0.001 ~~mg~~ to about 100 mg/kg/day ~~mg~~ of a hydrate form of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.